Brainsway Stock Forecast, Price & News

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Brainsway in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Brainsway stock.
View analyst ratings for Brainsway or view top-rated stocks.

Wall Street analysts have given Brainsway a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Brainsway wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Brainsway saw a increase in short interest in the month of January. As of January 29th, there was short interest totaling 25,700 shares, an increase of 272.5% from the January 14th total of 6,900 shares. Based on an average daily volume of 25,300 shares, the short-interest ratio is presently 1.0 days.
View Brainsway's Short Interest.

Brainsway is scheduled to release its next quarterly earnings announcement on Monday, March 22nd 2021.
View our earnings forecast for Brainsway.

Brainsway Ltd. (NASDAQ:BWAY) released its quarterly earnings results on Wednesday, November, 18th. The company reported ($0.04) earnings per share for the quarter, beating the consensus estimate of ($0.06) by $0.02. The company earned $6.01 million during the quarter, compared to analyst estimates of $5.35 million. Brainsway had a negative trailing twelve-month return on equity of 33.99% and a negative net margin of 34.28%.
View Brainsway's earnings history.

Brainsway's stock was trading at $8.19 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, BWAY stock has increased by 13.3% and is now trading at $9.28.
View which stocks have been most impacted by COVID-19.

Brainsway updated its fourth quarter 2020 Pre-Market earnings guidance on Tuesday, February, 16th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $6.8-7.1 million, compared to the consensus revenue estimate of $5.68 million.

3 equities research analysts have issued 1-year target prices for Brainsway's shares. Their forecasts range from $12.00 to $13.00. On average, they anticipate Brainsway's stock price to reach $12.67 in the next twelve months. This suggests a possible upside of 36.5% from the stock's current price.
View analysts' price targets for Brainsway or view top-rated stocks among Wall Street analysts.

Some companies that are related to Brainsway include Apyx Medical (APYX), UFP Technologies (UFPT), InfuSystem (INFU), T2 Biosystems (TTOO), Neuronetics (STIM), PAVmed (PAVM), The Westaim (WEDXF), Utah Medical Products (UTMD), Soliton (SOLY), IRadimed (IRMD), RenovaCare (RCAR), TELA Bio (TELA), DarioHealth (DRIO), Titan Medical (TMDI) and PolyPid (PYPD).
View all of BWAY's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Brainsway investors own include AbbVie (ABBV), Advanced Micro Devices (AMD), Enterprise Products Partners (EPD), Pfizer (PFE), Neuronetics (STIM), Boingo Wireless (WIFI), Ampio Pharmaceuticals (AMPE), Eastman Chemical (EMN), Enbridge (ENB) and Energy Transfer (ET).

(BWAY) raised $30 million in an initial public offering (IPO) on Wednesday, April 17th 2019. The company issued 2,500,000 shares at a price of $11.94 per share. Cantor served as the underwriter for the IPO.

Brainsway trades on the NASDAQ under the ticker symbol "BWAY."

Brainsway's stock is owned by many different retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (0.20%).

BWAY stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC.

Shares of BWAY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of BWAY stock can currently be purchased for approximately $9.28.

Brainsway has a market capitalization of $100.41 million and generates $23.10 million in revenue each year. The company earns $-10,330,000.00 in net income (profit) each year or ($0.50) on an earnings per share basis.

Brainsway employs 107 workers across the globe.

The official website for Brainsway is www.brainsway.com.

Brainsway is headquartered at 19 HARTUM STREET BYNET BUILDING 3RD FL Har HaHotzvim, Jerusalem L3, 9777518.

Brainsway's mailing address is 19 HARTUM STREET BYNET BUILDING 3RD FL Har HaHotzvim, Jerusalem L3, 9777518. The company can be reached via phone at (722) 581-3140 or via email at [email protected]